The Vaccine Adverse Event Reporting System (VAERS), the national passive surveillance (spontaneous reporting) system for adverse events after immunization, 6 captured notifications and reports of suspected anaphylaxis following vaccination. This analysis updates the reporting rates of anaphylaxis in individuals following receipt of either the Pfizer-BioNTech or Moderna vaccine. 3, 4 Since these early estimates were generated, millions more doses of both vaccines have been administered and safety monitoring has detected additional cases of anaphylaxis. 5 The initial estimated reporting rates for anaphylaxis in the US were 11.1 cases per million doses administered of the Pfizer-BioNTech vaccine (December 14-23, 2020) and 2.5 cases per million doses administered of the Moderna vaccine (December 21, 2020-January 10, 2021). 3, 4 Anaphylaxis is a life-threatening allergic reaction that can occur after vaccination, with onset typically within minutes to hours. 1, 2įollowing implementation of vaccination, cases of anaphylaxis after administration of the Pfizer-BioNTech and Moderna vaccines began to be reported. Shortly after each authorization, the Advisory Committee on Immunization Practices issued interim recommendations for use. In December 2020, the US Food and Drug Administration (FDA) issued Emergency Use Authorizations for 2 mRNA-based vaccines for prevention of coronavirus disease 2019 (COVID-19): Pfizer-BioNTech COVID-19 vaccine (EUA issued December 11 2 doses, 3 weeks apart) and Moderna COVID-19 vaccine (EUA issued December 18 2 doses, 1 month apart). Shared Decision Making and Communication. ![]() Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |